About Hualan Biological Engineering, Inc. Company

The company was founded in 1992 and is a national high-tech enterprise and a national innovative pilot enterprise engaged in R&D, production and sales of biological products such as blood products, vaccines, recombinant proteins, etc. Currently, there are 9 types of vaccine products on the market. It is the first quadrivalent influenza vaccine company approved for production in China. In the field of recombinant proteins, the company is actively developing monoclonal antibodies. Currently, several Hualan monoclonal antibody drugs have entered clinical trials. The company is a national high-tech enterprise engaged in R&D, production and sales of blood products, vaccines and genetic engineering products. The company's main products: human blood albumin, intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human fibrin gel, topical freeze-dried human thrombin, influenza virus lytic vaccine, influenza virus lysis vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hanson vaccine) yeast), group A group C meningococcal polysaccharide vaccine, quadrivalent influenza virus lysis vaccine, freeze-dried for human use Rabies vaccine (Vero cell), adsorbed tetanus vaccine. Corporate honors: National certified enterprise technology center title, national key new product certificate, Ukrainian GMP certification, etc.